Enter assignee name

EPO Patents = 5

Forward Citations = 124

Loading Chart...

7 inventors (with patents filed for the assignee):

Jamey Paul Weichert (12 out of 44 patents)

Marc Longino (12 out of 20 patents)

Anatoly Pinchuk (10 out of 29 patents)

4. Irawati Kandela (4 out of 5 patents)

5. William R Clarke (4 out of 7 patents)

6. Sharon Weber (1 out of 1 patent)

7. Joseph O Nwankwo (1 out of 1 patent)

12 patents: Sort by Forward Citations

1. 10004818 - Ether and alkyl phospholipid compounds for treating cancer and imaging and detection of cancer (2018-06-26),

2. 9339564 - Ether and alkyl phospholipid compounds for treating cancer and imaging and detection of cancer (2016-05-17),

3. 8877160 - Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof (2014-11-04),

4. 8877159 - Phospholipid analogs as diapeutic agents and methods thereof (2014-11-04),

5. 8871181 - Fluorescent phospholipid ether compounds, compositions, and methods of use (2014-10-28),

6. 8540968 - Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof (2013-09-24),

7. 8535641 - Phospholipid analogs as diapeutic* agents and methods thereof (2013-09-17),

8. 8022235 - Compositions of phospholipid ether boronic acids and esters and methods for their synthesis and use (2011-09-20),

9. 7893286 - Method for the synthesis of phospholipid ethers (2011-02-22),

10. 7811548 - Fluorescent phospholipid ether compounds and compositions (2010-10-12),

11. 7700075 - Virtual colonoscopy with radiolabeled phospholipid ether analogs (2010-04-20),

12. 7632644 - Imaging and selective retention of phospholipid ether analogs (2009-12-15),

Cellectar, Inc. is a clinical-stage biopharmaceutical company focused on the development of targeted therapies for oncology. With a proprietary phospholipid drug conjugate (PDC) delivery platform, Cellectar aims to selectively deliver various therapeutic payloads to cancer cells, resulting in enhanced efficacy and minimized side effects. Their lead PDC compound, CLR 131, is being evaluated in multiple clinical studies for the treatment of various types of cancer. For more information about the company and its innovative drug delivery solutions, please visit their official website.

This text is generated by artificial intelligence and may not be accurate.